<DOC>
	<DOCNO>NCT01607658</DOCNO>
	<brief_summary>The purpose study ass compare effect 3 dose strength TBS-2 intranasal testosterone gel placebo occurrence orgasm .</brief_summary>
	<brief_title>Efficacy Safety TBS-2 Testosterone Gel Women With Acquired Female Orgasmic Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Sexual Dysfunctions , Psychological</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Inclusion Criteria Subjects meet follow criterion may include study : At Visit 1 : ≤ Be generally healthy female age 18 year old , inclusive , physical impediment sexual function Have diagnosis acquire female orgasmic disorder define absence orgasm past 6 month accord Diagnostic Statistical Manual Mental Disorders IV ( DSMIV ) criterion . Subtype generalize due etiological factor would unlikely relate hormone function ( eg , depression , relationship discord , alcoholism , surgery , injury ) . Hypoactive sexual desire disorder comorbid disorder allow begin female orgasmic disorder diagnosis ; Have score &gt; 15 score ≥2 question # 15 FSDS DAO Screening Visit ; Be sexually active , hetero homosexual woman steady relationship least 6 month agree least 4 sexual event 28day period time . The subject 's partner untreated sexual dysfunction ; Be reliable birth control method ( ie , stable systemic hormonal contraception whole duration study 30 day study completion [ least 3 month prior study ] , IUD , barrier method ) engage heterosexual intercourse . Birth control method use subject screen change course study ; Have normal ENT examination ; Have body mass index ≤35 ; Have clinically acceptable pelvic examination Pap smear read license laboratory facility ( evidence malignancy ) within 2 year prior Randomization ; Have clinically acceptable mammogram ; Be able complete webbased questionnaire within 24 hour sexual event ; Be able read English provide write informed consent ; At Visit 2 : Have least 4 sexual event absence orgasm 28 day Screening/Baseline Period determine MONASH WHP FSSQ . Exclusion Criteria Subjects meet follow criterion eligible participate study : Have know history hypersensitivity testosterone component study drug ; Have history clinically relevant psychiatric disorder could impact sexual functioning , contribute increase risk patient safety , significantly compromise participation study ( eg , bipolar disorder , psychotic disorder , severe anxiety , eat disorder , borderline personality disorder , untreated Major Depressive Disorder ) ; Have score ≥14 Beck Depression Inventory II Screening Visit . Subjects score ≥14 ≤19 Screening may eligible participate study specialist ( psychologist psychiatrist ) conclude subject clinically depress ; Have concurrent female sexual dysfunction disorder define DSMIV criterion , eg , Sexual Aversion Disorder , SubstanceInduced sexual dysfunction , dyspareunia ( caused inadequate foreplay stimulation alleviate lubricant ) , vaginismus , Gender Identity Disorder , paraphilia , sexual dysfunction due general medical condition ; Be experience relational discord ; Have history dementia neurodegenerative disease , organic brain disease , stroke , transient ischemic attack , brain surgery , significant brain trauma , multiple sclerosis , spinal cord injury , peripheral neuropathy , epilepsy ( febrile seizure limit childhood exclude patient ) ; Be currently receive treatment selective norepinephrine reuptake inhibitor ( SNRIs ) selective serotonin reuptake inhibitor ( SSRIs ) and/or medication interfere metabolism testosterone ( eg , anastrozole , clomiphene , testolactone , ketoconazole , spironolactone , histamine 2 [ H2 receptor blocker , etc . ] ) ; Have history , current evidence , abuse alcohol drug substance , licit illicit , regular drinker 3 unit alcohol daily ( 1 unit = 300 mL beer , 1 glass wine , 1 measure spirit ) ; Have history cancer nonmelanotic skin cancer ; Have history deep venous thrombosis coagulation disorder ; Have significant medical condition ( eg , hepatic , renal cardiovascular , endocrine include diabetes mellitus ) . Subjects treated hypertension , treat hyperlipidemia , treat thyroid disease exclude provide stable therapy least 3 month ; Had major surgical procedure within past 6 month include hysterectomy , hysterectomy bilateral salpingo oophorectomy , vaginal incontinence surgery Are receive treatment systemic glucocorticosteroids , sex steroid hormone androgen ( eg , dehydroepiandrosterone [ DHEA ] ) gestagens ( eg , anabolic steroid ) use post menopausal hormone therapy ; Have history severe multiple drug allergy , severe adverse drug reaction drugrelated leucopenia ; Have history nasal disorder ( eg , atrophic rhinitis , polyposis , abuse nasal decongestant , clinically relevant nasal septum deviation , recurrent epistaxis ) , sinus disease nasal surgery and/or seasonal perennial allergic rhinitis active phase ; Be use form chronic intranasal medication delivery , specifically nasal corticosteroid decongestant ; Have diagnosis sleep apnea use continuous positive airway pressure/automatic positive airway device ; Have history diagnose hirsutism , alopecia clinically significant acne ; Have history diagnose polycystic ovarian syndrome ; Have pelvic inflammatory disease , chronic urinary tract , vaginal , cervical infection , interstitial cystitis , vulvodynia , significant symptomatic vaginal atrophy ; Are currently pregnant , history positive serum pregnancy test Screening Visit pregnant within 12 month prior Screening Visit ; Is breast feed breast fed within 6 month prior Screening Visit ; Are positive hepatitis Bsurface antigen , hepatitis C , Human Immunodeficiency Virus ( HIV ) ; Have abnormal thyroid stimulate hormone level ; For premenopausal woman , SHBG value &lt; 18 86 nmol/L ; For postmenopausal woman , SHBG value &gt; 160 nmol/L Have medical psychiatric condition , physical examination finding , laboratory result , opinion principal investigator , would put subject additional medical risk make unlikely able comply study requirement ; Have receive drug part research study within 30 day prior Screening Visit .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Testosterone</keyword>
</DOC>